Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Global Development, Inc.
With
Kyowa Kirin Co., Ltd.
Subjects will be followed for 6 months. Upon completion of the first 6 months of the study, subjects may participate in the Long Term Extension period of the study. Subjects will remain on their original treatment arm up to three years post-transplant (and / or Sponsor discontinues development or the subject no longer wishes to participate in the study).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject is a recipient of a de novo kidney from a living or deceased donor
You may not be if
Subject has induction therapy, other than study-assigned basiliximab, planned as part of initial immunosuppressive regimen
Subject has previously received or is receiving an organ transplant other than a kidney
Subject will receive a solitary kidney from a deceased donor \< 5 years of age
Subject will receive a kidney with an anticipated cold ischemia time (CIT) of \> 30 hours
Subject will receive a kidney that meets both Extended Criteria Donor (ECD) and Donation after Cardiac Death (DCD) criteria. Note: a kidney that meets either ECD or DCD criteria is eligible for inclusion
Subject will receive an ABO incompatible donor kidney
Subject has a current calculated panel reactive antibody (cPRA) level \>50%
